Tackling population health challenges means asking big questions, such as:
And how do you even know which are the right questions to ask?
Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.
We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.
And that will help you choose the best way forward.
Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.Why Us?
We’ve created a specific process to help you find, ask and answer the right questions.Method
We’ve answered many different kinds of questions for many different organisations in over 70 countries.Track Record
We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.Team
The Institute of Alcohol Studies has today released a report “Estimating the long-term health impacts of changes in alcohol consumption in England during the COVID-19 pandemic” which includes modelling undertaken by HealthLumen. The pandemic saw heavier drinkers consuming more alcohol and this trend is continuing. If consumption does not return to 2019 levels or lower, the modelling shows […]Read
Our latest modelling project, undertaken for the Institute of Alcohol Studies, looks at how pandemic drinking patterns could impact alcohol-related disease and death.Read
We all know that too much salt is bad for our health! Consuming too much salt can lead to high blood pressure which can lead to a variety of different health conditions including stroke and coronary heart disease. These diseases combined, claim the lives of millions of people globally, and costs the NHS, as well […]Read
Of the three main phases of clinical trials, by far the most expensive part of the process is the Phase 3 trial, typically requiring from several hundred to several thousand participants and costing up to $20 million on average. Furthermore, the process is fraught with risks with up to 70% of Phase 2 trials and […]Read